Literature DB >> 22375517

Targeting opioidergic pathways as a novel biological treatment for advanced pancreatic cancer.

Ian S Zagon, Patricia J McLaughlin.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22375517     DOI: 10.1586/egh.11.106

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


× No keyword cloud information.
  4 in total

1.  Combined Treatment with Autologous CIK Cells, Radiotherapy and Chemotherapy in Advanced Cervical Cancer.

Authors:  Ning Li; Yong-Wei Tian; Yue Xu; Dan-Dan Meng; Ling Gao; Wen-Jie Shen; Zong-Lan Liu; Zhi-Qiao Xu
Journal:  Pathol Oncol Res       Date:  2018-12-03       Impact factor: 3.201

2.  Methionine enkephalin (MENK) improves lymphocyte subpopulations in human peripheral blood of 50 cancer patients by inhibiting regulatory T cells (Tregs).

Authors:  Qiushi Wang; Xinghua Gao; Zhe Yuan; Zhe Wang; Yiming Meng; Yan Cao; Nicolas P Plotnikoff; Noreen Griffin; Fengping Shan
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Inhibition of the growth of human melanoma cells by methionine enkephalin.

Authors:  Dong-Mei Wang; Guang-Chuan Wang; Jing Yang; Nicolas P Plotnikoff; Noreen Griffin; Yu-Man Han; Rui-Qun Qi; Xing-Hua Gao; Feng-Ping Shan
Journal:  Mol Med Rep       Date:  2016-11-14       Impact factor: 2.952

4.  Survival features, prognostic factors, and determinants of diagnosis and treatment among Iranian patients with pancreatic cancer, a prospective study.

Authors:  Mahdi Sheikh; Sahar Masoudi; Razieh Bakhshandeh; Alireza Moayyedkazemi; Farhad Zamani; Sepideh Nikfam; Masoumeh Mansouri; Neda Ghamarzad Shishavan; Saman Nikeghbalian; Paul Brennan; Reza Malekzadeh; Akram Pourshams
Journal:  PLoS One       Date:  2020-12-04       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.